USPTO serial 90796010
EPICENTRX
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOVELACE, JAMES B
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EPICENTRX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
La Jolla, CA, US
La Jolla, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Muzamil Huq
Muzamil Huq MORRISON & FOERSTER LLP425 MARKET STREETSAN FRANCISCO, CA 94105United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases | ACTIVE | — |
| 042 | Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 2, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 2, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 12, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 11, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 11, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 1, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 30, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 4, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 4, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 3, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 2, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 2, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 2, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 2, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 5, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 3, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 3, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 3, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 22, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 22, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 22, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 5, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 3, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 3, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 3, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 3, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 8, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 8, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 19, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 3, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 22, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 22, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 29, 2021 | NWAP | NEW APPLICATION ENTERED | — |